Suppr超能文献

系统回顾和荟萃分析开放和血管内修复腹主动脉瘤的早期和晚期结果。

Systematic review and meta-analysis of the early and late outcomes of open and endovascular repair of abdominal aortic aneurysm.

机构信息

Vascular Surgery Group, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.

出版信息

Br J Surg. 2013 Jun;100(7):863-72. doi: 10.1002/bjs.9101. Epub 2013 Mar 8.

Abstract

BACKGROUND

Any possible long-term benefit from endovascular (EVAR) versus open surgical repair for abdominal aortic aneurysm (AAA) remains unproven. Long-term data from the Open Versus Endovascular Repair (OVER) trial add to the debate regarding long-term all-cause and aneurysm-related mortality. The aim of this study was to investigate 30-day and long-term mortality, reintervention, rupture and morbidity after EVAR and open repair for AAA in a systematic review.

METHODS

Standard PRISMA guidelines were followed. Random-effects Mantel-Haenszel meta-analysis was performed to evaluate mortality and morbidity outcomes.

RESULTS

The existing published randomized trials, together with information from Medicare and SwedVasc databases, were included in a meta-analysis. This included 25 078 patients undergoing EVAR and 27 142 undergoing open repair for AAA. Patients who had EVAR had a significantly lower 30-day or in-hospital mortality rate (1·3 per cent versus 4·7 per cent for open repair; odds ratio (OR) 0·36, 95 per cent confidence interval 0·21 to 0·61; P < 0·001). By 2-year follow-up there was no difference in all-cause mortality (14·3 versus 15·2 per cent; OR 0·87, 0·72 to 1·06; P = 0·17), which was maintained after at least 4 years of follow-up (34·7 versus 33·8 per cent; OR 1·11, 0·91 to 1·35; P = 0·30). There was no significant difference in aneurysm-related mortality by 2 years or longer follow-up. A significantly higher proportion of patients undergoing EVAR required reintervention (P = 0·003) and suffered aneurysm rupture (P < 0·001).

CONCLUSION

There is no long-term survival benefit for patients who have EVAR compared with open repair for AAA. There are also significantly higher risks of reintervention and aneurysm rupture after EVAR.

摘要

背景

血管内(EVAR)与开放手术修复腹主动脉瘤(AAA)的长期获益仍未得到证实。来自开放与血管内修复(OVER)试验的长期数据增加了关于长期全因和动脉瘤相关死亡率的争论。本研究旨在通过系统评价调查 EVAR 和开放修复 AAA 后 30 天和长期死亡率、再干预、破裂和发病率。

方法

遵循标准 PRISMA 指南。采用随机效应 Mantel-Haenszel 荟萃分析评估死亡率和发病率结果。

结果

本 meta 分析纳入了已发表的随机试验以及 Medicare 和 SwedVasc 数据库的信息,共包括 25078 例行 EVAR 和 27142 例行开放修复的 AAA 患者。EVAR 组的 30 天或住院内死亡率显著较低(1.3%比开放修复组的 4.7%;比值比[OR] 0.36,95%置信区间 0.21 至 0.61;P<0.001)。在 2 年随访时,全因死亡率无差异(14.3%比 15.2%;OR 0.87,0.72 至 1.06;P=0.17),且在至少 4 年随访后仍保持(34.7%比 33.8%;OR 1.11,0.91 至 1.35;P=0.30)。2 年或更长时间的随访时,动脉瘤相关死亡率无显著差异。EVAR 组需要再次干预的患者比例显著更高(P=0.003),且动脉瘤破裂的风险更高(P<0.001)。

结论

与开放修复相比,EVAR 治疗 AAA 患者没有长期生存获益。EVAR 后再干预和动脉瘤破裂的风险也显著更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验